Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.45 |
| ▸ | FPR2 | P25090 | 8/20 | 0.45 |
| ▸ | RORC | P51449 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | FPR1 | P21462 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966861 | 0.93 | RORC (0.45) | USP30PDE4BFPR2RORCHDAC1 | |
| SCHEMBL1973522 | 0.89 | PDE4B (0.45) | USP30PDE4BFPR2RORCHDAC1 | |
| SCHEMBL1970588 | 0.88 | TACR1 (0.49) | PDE4BFPR2RORCHDAC1HDAC2 | |
| SCHEMBL1972466 | 0.88 | TACR1 (0.49) | PDE4BFPR2RORCHDAC1HDAC2 | |
| SCHEMBL30693163 | 0.88 | TACR1 (0.49) | PDE4BFPR2RORCHDAC1HDAC2 | |
| SCHEMBL30693160 | 0.88 | TACR1 (0.49) | PDE4BFPR2RORCHDAC1HDAC2 | |
| SCHEMBL1968872 | 0.88 | TACR1 (0.49) | PDE4BFPR2RORCHDAC1HDAC2 | |
| SCHEMBL15397592 | 0.85 | FPR2 (0.41) | FPR2FPR1 | |
| SCHEMBL1968280 | 0.84 | RORC (0.46) | PDE4BFPR2RORCHDAC1HDAC2 | |
| SCHEMBL30693187 | 0.84 | RORC (0.46) | PDE4BFPR2RORCHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | USP30 4000/4885PDE4B 3803/4885FPR2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.